Elite Pharmaceuticals Inc Stock OTC Bulletin Board
Equities
US28659T2006
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 20 | Elite Pharmaceuticals Receives Fda Approval for Generic Methotrexate | CI |
Feb. 15 | Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024 |
Financials (USD)
Sales 2022 | 32.26M | Sales 2023 | 34.16M | Capitalization | 29.4M |
---|---|---|---|---|---|
Net income 2022 | 8M | Net income 2023 | 3M | EV / Sales 2022 | 0.92 x |
Net cash position 2022 | 5.75M | Net cash position 2023 | 3.94M | EV / Sales 2023 | 0.75 x |
P/E ratio 2022 |
4.73
x | P/E ratio 2023 |
9.34
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.76% |
Latest transcript on Elite Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Nasrat Hakim
CEO | Chief Executive Officer | 63 | 13-07-31 |
Carter Ward
DFI | Director of Finance/CFO | 59 | 09-06-30 |
Christopher Dick
PSD | President | 69 | 02-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Whitnell
BRD | Director/Board Member | 68 | 09-10-22 |
Barry Dash
BRD | Director/Board Member | 93 | 05-03-31 |
Davis Caskey
BRD | Director/Board Member | 76 | 16-04-27 |
1st Jan change | Capi. | |
---|---|---|
+20.37% | 43.39B | |
+19.44% | 22.01B | |
+18.29% | 15.46B | |
+25.55% | 14.93B | |
+60.99% | 13.13B | |
-0.05% | 6.79B | |
-15.02% | 6.36B | |
-8.87% | 5.73B | |
+10.57% | 5.43B |